The design and synthesis of two Janus-type heterocycles with capacity to simultaneously recognize guanine and uracyl in G-U mismatched pairs through complementary hydrogen bond pairing is described. Both compounds were conveniently functionalized with a carboxylic function and efficiently attached to a tripeptide sequence by using solid-phase methodologies. Ligands based on the derivatization of such Janus compounds with a small aminoglycoside, neamine, and its guanidinylated analogue have been synthesized, and their interaction with Tau RNA has been investigated by using several biophysical techniques, including UV-monitored melting curves, fluorescence titration experiments and 1 H NMR.
INTRODUCTION
Targeting RNA with small molecules, particularly human disease-causing RNAs, has enormous potential in medicinal chemistry.
1 In addition to the notable case of compounds targeting bacterial ribosomal RNA, 1 recent examples have demonstrated that the function of other RNA sequences can be modulated with synthetic small molecules. 2 Similarly to proteins, RNA is able to fold local structural motifs such as stem-loops, bulges or internal loops into complex three-dimensional architectures, thus generating targetable binding sites where ligands can be accommodated. The simultaneous recognition of such targetable motifs by compounds based on the combination of fragments is an attractive approach to develop ligands with increased RNA affinity and specificity. 1, 3 Moreover, this fragmentbased approach might also be used to confer them with desirable drug-like properties such as cellular permeability. 4 Among the large variety of RNA structural motifs, the G-U wobble base-pair 5 plays an essential role in many biological processes since it is recognized by proteins and other RNAs. 6 Despite its comparable thermodynamic stability to Watson-Crick base pairs, several studies have revealed that G-U wobble pairs are more prone to base-opening than canonical pairs, 7 which would facilitate their recognition through complementary hydrogen bond pairing by using nicknamed Janus-type molecules. As the two-faced Roman god, Janus-type heterocycles have two hydrogen bonding arrays complementary to the faces of a given pair of nucleobases. 8 Insertion of such compounds between the two nucleobases is expected to provide higher affinity and specificity since the number of hydrogen bonds will be increased. Most of Janus molecules reported have been incorporated into DNA, PNA analogues or peptides with negatively-charged backbone with the aim of forming triplex or duplex structures upon bifacial recognition of target nucleobases. 9 Diaminotriazine conjugation to an acridine derivative has also been explored for targeting U-U mismatch sites in CUG repeats in RNA associated with the development of myotonic dystrophy type 1 disease. Of current interest to our laboratory 11 is the development of ligands for the RNA secondary structure located at the exon 10-5' intron junction of Tau pre-mRNA since it has been proposed as a therapeutic target for the treatment of several tauopathies, including frontotemporal dementia with parkinsonism linked to chromosome . 12, 13 Interestingly, wild-type Tau RNA has two G-U pairs (G+5 and G-4) , and some of the disease-causing mutations (+13, +14 and +16) found in FTDP-17 patients form additional G-U pairs (see Figure 1 ) that diminish the thermodynamic stability of the stem-loop structure. This modifies exon 10 alternative splicing and, as a consequence, the correct ratio of tau protein isoforms is altered, which leads to dementia. 14 Significantly, early NMR studies reported by Varani et al. 12a suggested that wobble G-U pairs are only formed in the case of +13 and +14 mutated sequences, whereas G-1 (+16 mutated sequence) and G+5 and G-4 (wt, +3 and +16) are not paired with their faced U's. On the basis of these precedents, we have envisaged that such G-U pairs might be used to selectively target Tau RNA with
The 1D NOE irradiation of the proton at 9.36 ppm showed a clear NOE enhancement of the aldehyde proton whereas that phenomenon did not occur for the proton at 6.28 ppm, which allowed the unambiguous distinction of both isomers.
A second nucleophilic aromatic substitution with aqueous ammonia afforded compound 5 in quantitative yield. It is interesting to mention that S N Ar occurs exclusively at position 2 when the reaction is carried out at room temperature for 5 h, whereas a large excess of ammonia and higher temperature gives substitution at positions 2 and 6. Similar results have been reported with other derivatives of 2,6-dichloropyrimidine that contain an amino substituent at position 4 and electronwithdrawing groups (aldehyde or ester) at position 5 of the ring. 15b,c,16,17 The next step was the reduction of the aryl chloride group by H 2 with 10% Pd-C in the presence of sodium acetate, which afforded 6 with 56% yield after chromatographic purification. Notably, the aldehyde group was not reduced under the conditions used for carrying out catalytic hydrogenation. The primary aromatic amino function was bis-Boc protected by reaction with tert-butoxycarbonyl anhydride in DMF in the presence of a catalytic amount of DMAP. Besides 7 (29% yield after purification), several side products were identified, including those derived from monoprotection of both amino functions.
Then, the aldehyde was transformed in oxime (8) in 88% yield, and dehydration with trifluoroacetic anhydride produced the fluorescent nitrile derivative 9 (79%). The critical step of the synthesis route involved the transformation of the free secondary amino function into an activated urea derivative to allow cyclization in basic media. To our surprise, this aromatic amine function was found very unreactive, since no evidence of reaction was obtained when using triphosgene, phosgene, trimethylsilyl isocyanate or chlorosulfonyl isocyanate. Reaction with N-chlorocarbonyl isocyanate 15b at -10ºC in the presence of triethylamine afforded in very low yield the N-chlorocarbonylurea derivative. Finally, reaction with trichloroacetyl isocyanate at 0ºC in anhydrous DCM under an Ar atmosphere 6 produced compound 10 in nearly quantitative yield after flash column chromatography.
Cyclization in a concentrated methanolic solution of ammonia afforded the key compound (11, 80% yield) that contains both Janus faces. Boc-protection of the free amino group followed by basic hydrolysis of the ester yielded the final JanusA monomer 1 as a clear yellow solid, which was fully characterized by HR-ESI MS and 1 H and 13 C NMR.
Scheme 1. Synthesis of Janus A monomer (1).
Compound 2 was prepared in 4 steps and 47% average stepwise yield (Scheme 2) from malononitrile, urea and triethyl orthoformate. The key step involved the condensation of the nitrile group of 5-cyanocytosine 18 with dicyandiamide 19 in dry ethylene glycol in the presence of KOH at 150ºC for 40 h, which afforded 15 as a brown solid in 54% yield. Mild condition reactions, such as those reported for the construction of diaminotriazine from 5-cyanouracyl 19c failed in this case and more energetic conditions were required (e.g. prolonged heating at 150ºC or assisted by microwave irradiation). The next step involved alkylation of N1 of the cytosine ring with ethyl bromobutyrate by using NaH in DMF.
Hydrolysis of the intermediate with LiOH afforded the expected Janus B monomer (2).
According to previous studies on the incorporation of triazine-containing amino acids onto peptides by solid-phase methodologies, 20 we decided not to protect the amino groups of the triazine moiety. Interestingly, 1 H NMR spectra of compound 2 suggests the formation of an intramolecular hydrogen bond between the exocyclic amino group of cytosine and the N2 of the triazine ring, which might protect it from acylation during amide bond formation.
Scheme 2. Synthesis of Janus B monomer (2).
Synthesis and characterizacion of Janus-containing ligands.
Targeting G-U mismatched pairs in Tau RNA or in other RNA secondary structures with Janus-type molecules requires conferring them with capacity to selectively recognize RNA from DNA. Aminoglycosides fulfill this requirement since they are able to discriminate Atype from B-type duplexes and have relatively high affinity for RNA. 21 However, these natural antibiotics lack of RNA sequence specificity, so they are considered promiscuous compounds. In spite of this drawback, aminoglycosides are privileged building blocks for designing new RNA ligands. 22 Recently, we have described a series of ligands for Tau RNA based on the combination of neamine and its guanidinylated analogue, guanidinoneamine, with heteroaromatic compounds such as acridines and an azaquinolone derivative with capacity to recognize unpaired adenines. 11 Based on these precedents, our next objective was the derivatization of Janus A and B heterocycles with these small glycosides. It is worth noting that replacement of the amino functions of neamine by guanidinium groups is expected to improve uptake by eukaryotic cells, as well as the RNA 8 binding affinity and stabilizing capacity of the ligands. 23 The synthesis of the ligands and their structures are shown in Scheme 3. Since the distance between both building blocks can be a critical parameter in ligands based on the combination of fragments, we used two thiol-containing neamine derivatives (Nea and Nea2) 11 differing in the length of the spacer between the thiol group and the glycoside core.
First, both Janus heterocycles were derivatized with a cysteine-containing peptide since the reactive thiol group was planned to be used for the attachment to the aminoglycoside via the formation of a disulfide linkage. Moreover, the guanidinium and carboxamide groups provided by arginine and asparagine, respectively, could generate additional interactions with RNA (e.g. hydrogen bonding and/or electrostatic). The tripeptide was assembled on a Rink amide p-MBHA resin using standard Fmoc/tBu chemistry. Janus monomers 1 and 2
were efficiently attached into the N-terminus of the peptide by using HATU as a coupling reagent. Cleavage and deprotection with TFA/TIS/H 2 O 95:2.5:2.5 for 1 h at rt, afforded the target compounds (18 and 19, Scheme 3) with high purity according to HPLC analysis.
This confirms that it is not necessary to protect the exocyclic amino function of cytosine in monomer 2.
Janus-Neamine ligands (20) (21) (22) (23) were easily synthesized in a two-step process which implicates two consecutive thiol-disulfide exchange reactions. First, thiol-derivatized neamine monomers (Nea or Nea2) 11 were activated with 2,2'-dithiobis(5-nitropyridine) (DTNP) 24 under acidic conditions for 15 h under Ar atmosphere. Then, the disulfide intermediates were reacted with the thiol-containing Janus-peptide monomers (18 or 19) , which afforded the desired ligands (20) (21) (22) (23) after purification by reversed-phase HPLC (yields 21-53%). All the compounds were fully characterized by NMR (1D 1 H, COSY, TOCSY) and high-resolution ESI mass spectrometry.
As shown in Scheme 3, the guanidinylated ligands (24) (25) (26) (27) were prepared by direct guanidinylation of their precursors (20) (21) (22) (23) following previously reported procedures. n=2 JanusB-Nea2 (23) JanusB-Nea2G4 (27) Scheme 3. Synthesis of Janus-Neamine/Guanidinoneamine ligands. A) Solid-phase synthesis of thiol-containing Janus-peptide derivatives; B) synthesis, and C) structure of Janus-containing ligands.
Studies on the interaction of Janus-containing ligands with Tau RNA.
Our next objective was to study the interaction of Janus-Neamine ligands (20) (21) (22) (23) and their guanidinylated derivatives, Janus-Guanidinoneamine (24) (25) (26) (27) , with Tau RNA, and in particular to evaluate their ability to stabilize Tau RNA. Besides wt we choose two of the mutated sequences associated with the development of tauopathies, +3 and +16. As previously mentioned, all of them contain two G-U mismatched pairs and +16 mutation generates an additional G-U mismatched pair adjacent to the bulged adenine. UV melting experiments were carried out by monitoring the absorbance at 260 nm as a function of temperature, which allowed to determine the melting temperature (T m ) as indicative of the thermal stability of the RNA secondary structure (Figure 2) . ∆T m values in Table 1 show the effect of the ligands on the T m of RNA upon complexation. 
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As shown in Table 1 , the effect of Janus-Neamine ligands on the thermal stability of wt RNA was almost negligible, being similar to that obtained with the free aminoglycoside.
However, this effect was positive in the case of the mutated sequences being particularly higher with the +3 mutant. Interestingly, the effect of the length of the spacer linking both fragments was different depending on the nature of the RNA sequence: the shorter spacer caused a greater increase in the T m values for +3 RNA (∆T m = +5.0 ºC for JanusA-Nea vs ∆T m = +6.1 ºC for JanusA-Nea2) whereas the opposite tendency was found for +16 RNA (∆T m = +1.9 ºC for JanusA-Nea vs ∆T m = +1.0 ºC for JanusA-Nea2). This suggests that the binding site of these compounds might be different depending on the secondary structure of the RNA target. To our surprise, the stabilizing ability of the ligands was independent on the nature of the Janus-type heterocycle. However, the fact that the T m values of JanusNeamine ligands were slightly higher than those of neamine alone with +3 and +16 RNAs seems to suggest that the Janus-peptide fragment might participate in RNA binding.
Moreover, the higher stabilization of +3 RNA compared with that of +16 (e.g. JanusANea2, ∆T m = +6.1 ºC for +3 vs ∆T m = +1.0 ºC for + 16) might be a consequence of some kind of selectivity for this RNA mutated sequence.
These results prompted us to evaluate the ability of Janus-Guanidinoneamine ligands (24) (25) (26) (27) to stabilize the +3 mutated sequence. As shown in Table 2 , guanidinylation of the aminoglycoside moiety in Janus-Neamine ligands had always a positive effect on the thermal stability of the RNA upon complexation. This effect was particularly important in the two ligands with the shorter spacer independently of the Janus heterocycle (∆T m G = +3.8 ºC for JanusA-Nea2G4 and JanusB-Nea2G4). However, the additional stabilization provided by the guanidinium groups was lower in the case of the ligand with the longer spacer that contains JanusB heterocycle (e.g. ∆T m G = +3.3 ºC for JanusA-NeaG4 vs ∆T m G = +1.4 ºC for JanusB-NeaG4). Table 2 . Melting temperatures (T m ) for the complexation of ligands with target RNAs (1 µM both in RNA and in ligands in 10 mM sodium phosphate buffer, pH 6.8, 50 mM NaCl and 0.1 mM Na 2 EDTA).
[a] ∆T m = (T m of the RNA in the presence of ligand) -(T m of RNA alone). (the effective ligand concentration required for 50% RNA response) to be obtained by fitting the data to a sigmoidal dose-response curve. To our surprise, upon addition of increasing concentrations of Janus-containing ligands, either Janus A or Janus B, the fluorescence intensity of the fluorescein-labeled RNA increased (upon excitation at 490 nm) and the maximum was shifted from the typical 517 nm value to 522-525 nm. This behaviour might be attributed to the presence of several binding sites in the RNA structure or to the interaction of the ligands with fluorescein. 26 As an alternative to fluorescein, we choose the fluorescent nucleotide analogue 2-aminopurine-2'-deoxyribonucleotide (2-AP), which has also been widely used to determine binding affinities for RNA. 27 In order to minimize alterations in the structure and stability of +3 Tau RNA, we decided to replace the adenine base of the loop with 2-AP. Again, changes in 2-AP fluorescence intensity upon excitation at 290 nm were measured as a function of the concentration of the ligands.
∆T m G [b] No (Table 3 ) could be determined with 2-APlabelled +3 RNA. As shown in Figure 2 , the fluorescence of 2-AP decreased upon addition of increasing concentrations of the ligands, while the wavelength of the fluorescence maximum stayed constant. In this case, the inherent fluorescence of the ligand could be efficiently substracted from that of the labelled RNA by repeating the full titration in the absence of RNA. Two main conclusions can be drawn from EC 50 values reported in Table   3 . First, binding affinities of the ligands are relatively high (120-300 nM) and the length of the spacer seems to be a critical parameter since the binding was observed to be stronger for the ligands containing the shorter spacer linking both fragments, independently of the glycoside moiety (EC 50 = 296 nM for JanusB-Nea vs EC 50 = 213 nM for JanusB-Nea2).
Second, guanidinylation of the aminoglycoside had a positive influence on binding affinity, which was slightly higher in the case of the ligand with the shorter spacer (EC 50 = 213 nM for JanusB-Nea2 vs EC 50 = 122 nM for JanusB-Nea2G4). Table 3 . Binding of the ligands to +3 RNA.
[a] All fluorescence measurements were performed in 10 mM sodium phosphate buffer pH 6.8, 50 mM NaCl and 0.1 mM Na 2 EDTA.
All together, these results show a good correlation between binding affinities of JanusBcontaining ligands and their ability to stabilize Tau RNA. Indeed, the T m values of +3 RNA were increased in the presence of the ligands that had shown higher binding affinities.
Although binding affinities could not be determined for JanusA-containing ligands, according to T m values reported in Tables 1 and 2 , it is expected for these compounds to have similar EC 50 values than JanusB-containing ligands.
Finally, preliminary NMR studies were carried out to check if Janus-containing ligands can recognize G-U mismatched pairs through the formation of complementary hydrogen bonds.
Ligand EC50 (nM) [a] JanusB-Nea 296.7 + 63 JanusB-NeaG4 216.2 + 20 JanusB-Nea2 213. 4 + 45 On the lack of a well-defined structure for the +3 mutated sequence, we choose wt RNA as a model for studying the effect of ligand addition on its 1D 1 H NMR spectra, particularly on the imino and aromatic region. The structure of this oligoribonucleotide and its complexes with neomycin and mitoxantrone have been studied by Varani et al., 12a, 13c and they can be used as a reference for interpreting changes on the NMR spectra of Tau RNA in the presence Janus-containing ligands. As shown in Figure 3 , the addition of JanusA-Nea2
or JanusB-Nea2 caused a general line broadening of all signals but no significant changes in the chemical shifts of the imino protons. For example, the imino resonance of G+1 (δ:
12.65 ppm) and G-1 (δ: 12.84 ppm) were slightly shifted in both RNA-ligand complexes (δ:
12.55 and 12.78 ppm, respectively), whereas U0 and U+2 imino resonances collapsed into a single broad signal. Additionally, changes of the chemical shifts at higher fields than the imino resonances, particularly in the region between 5.5 and 8.5 ppm, might be attributed to non-exchangeable groups of the neamine moiety. Interestingly, a new signal around δ: 9.55 ppm (relative integration 1) appeared in the case of JanusB-Nea2 ligand. Taken together, these effects on the NMR spectra suggest that Janus-type heterocycles, either JanusA or JanusB, do not seem to bind any of the two G-U mismatched pairs in wt RNA since no new imino signals are formed in the region between 10 and 14 ppm. However, small changes in the chemical shifts of the imino resonances in the upper helical region (e.g., G-1, U0, G+1
and U + 2) might be related with electrostatic and/or hydrogen bond interactions with RNA through the major groove, in a similar way than neomycin does. 13a However, we can not rule out the formation of selective hydrogen bonds between Janus-type heterocycles and other RNA nucleobases. Furthermore, these Janus-type building blocks might be used in the future to develop specific ligands for targeting G-U pairs in other human disease-causing RNAs.
EXPERIMENTAL SECTION
Unless otherwise stated, common chemicals and solvents (HPLC grade or reagent grade quality) were purchased from commercial sources and used without further purification.
Aluminium plates coated with a 0.2 mm thick layer of silica gel 60 F 254 were used for thinlayer chromatography analyses (TLC), whereas flash column chromatography purification was carried out using silica gel 60 (230-400 mesh). Reversed-phase high-performance liquid chromatography (HPLC) analyses of the compounds were carried out on a Jupiter was slowly added at -78ºC under Ar atmosphere. The resulting mixture, which immediately acquired a yellow colour, was stirred at -78ºC for 6 h. Once at rt, the reaction mixture was taken up and washed with water (2 x 50 mL) and brine (50 mL). The resulting organic phase was dried over anhydrous MgSO 4 , filtered and concentrated in vacuo to dryness.
After flash column chromatography (gradient: 2.5-20% AcOEt in hexane), the desired compound (4a) was obtained as a yellow crystalline solid (8.53 g, 60%) . In addition, regioisomer 4b was also isolated as a minor product. 165.2, 163.9, 160.5, 114.4, 60.9, 41.5, 31.6, 24.4, 14.4 stirring for 5 h at rt, the reaction mixture was evaporated to dryness. The residue was dissolved in AcOEt (100 mL) and washed with water (2 x 50 mL) and brine (50 mL). The organic phase was taken up, dried over anhydrous MgSO 4 , filtered and concentrated in vacuo to dryness, providing the desired product as a yellow solid (7.84 g, quantitative yield), which was used without futher purification in the next step. TLC: R f (50% 188.9, 173.1, 166.7, 162.9, 162.4, 102.7, 60.7, 39.9, 31.7, 24.7, 14.3 190.8, 172.9, 165.3, 161.3, 160.3, 150.4, 110.3, 83.9, 60.7, 39.9, 31.7, 27.9, 24.6, 14.3 
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Ethyl 4-((2-bis(tert-butoxycarbonyl)amino-5-((hydroxyimino)methyl)pyrimidin-4-yl)amino)butanoate (8) . To a solution of compound 7 (4.22 g, 9.33 mmol) in pyridine (100 mL), hydroxylamine hydrochloride (1.3 g, 18.7 mmol) was added and the mixture was stirred under Ar for 6 h. The solvent was evaporated in vacuo and after several coevaporations from toluene, the residue was dissolved in AcOEt (100 mL). The organic phase was washed with water (50 mL) and brine (50 mL), dried over anhydrous MgSO 4 , filtered and concentrated in vacuo to dryness. The desired compound (8) 
Ethyl 4-((2-bis(tert-butoxycarbonyl)amino-5-cyanopyrimidin-4-yl)amino)butanoate (9).
To a solution of compound 8 (3.85 g, 8.24 mmol) in anhydrous THF (100 mL), triethylamine (3.7 mL, 24.72 mmol) was added under Ar. Then, the solution was cooled to 0ºC and trifluoroacetic anhydride (1.7 ml, 12.36 mmol) was added slowly while stirring.
The mixture was allowed to warm and stirred for 2 h at rt. The mixture was cooled back to 0ºC, and cold water (2 mL) was added to destroy the excess of TFAA, and the solvent was evaporated in vacuo. The residue was dissolved in AcOEt (50 mL), washed with 10% citric acid (25 mL), 10% NaHCO 3 (25 mL) and brine (25 mL Ethyl 4-(1-(2-bis(tert-butoxycarbonyl)amino-5-cyanopyrimidin-4-yl)-3-(2,2,2-trichloroacetyl)ureido)butanoate (10). To a solution of compound 9 (1 g, 0.636 mmol) in anhydrous DCM (5 mL), a solution of trichloroacetyl isocyanate (0.78 mL, 6.36 mmol) in anhydrous DCM (9 mL) was added dropwise at 0ºC over a period of 10 min under Ar atmosphere. After stirring for 1 h at 0ºC, the reaction mixture was allowed to warm to rt and stirred for an additional 5 h. The reaction mixture was cooled to 0ºC and quenched with cold water (25 mL 
Ethyl 4-(4-amino-7-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl)butanoate (11).
Compound 10 (1.42 g, 2.23 mmol) was stirred in 7 N NH 3 in MeOH (50 mL) under Ar atmosphere at -10ºC (ice-NaCl bath) for 2 h. After evaporation in vacuo, the resulting solid was dissolved in DCM (30 mL). The organic phase was washed with water (3 x 25 mL), dried over anhydrous MgSO 4 , filtered and evaporated in vacuo.
The desired compound (11) was obtained as a yellow solid (878 mg, 80.1%) and used without further purification in the next step. TLC: R f (15% MeOH/AcOEt): 0.68; IR (NaCl): ν = 3400, 1738. 8, 1652.6, 1635.5, 1602.3, 1558.9 4, 160.4, 158.7, 156.8, 155.9, 150.2, 101.1, 84.5, 60.6, 41.4, 31.8, 27.9, 23.3, 14.3 6, 161.2, 159.3, 158.0, 157.9, 155.6, 149.9, 148.2 105.6, 84.9, 84.5, 60.7, 41.5, 31.6, 28.1, 27.9, 23 5, 1764.3, 1751.3, 1728.6, 1661.5, 1602.3 4, 162.6, 161.2, 159.3, 158.0, 155.5, 149.9, 148.1, 105.6, 84.6, 82.1, 41.3, 31.1, 28.1, 27.9, 22.9 4-(5-(4,6-Diamino-1,3,5-triazin-2-yl)cytosine-1(2H)-yl)butanoic acid (2). To a solution of compound 15 (630 mg, 2.86 mmol) in anhydrous DMF, NaH 60% dispersion in mineral oil (114.4 mg, 2.86 mmol) was added under Ar atmosphere and the reaction mixture was stirred at 50ºC for 2 h. Then, ethyl bromobutyrate (450 µL, 3.15 mmol) was slowly added dropwise and the mixture was stirred at rt for 15 h. After evaporation in vacuo, the residue was dissolved in 30% MeOH in H 2 O (200 mL) at 70ºC, and then allowed to warm to rt. 9, 167.7, 166.0, 163.9, 154.4, 149.6, 100.3, 49.0, 30.7, 24.4 Solid-phase synthesis of Janus-peptide derivatives (18 and 19) . Synthesis of Janus-Neamine ligands (20) (21) (22) (23) .
General procedure. To a solution of 2,2'-dithiobis(5-nitropyridine) (7.8 mg, 25 µmol) in THF (2 mL) was added under argon a solution of the neamine thiol derivative (Nea or and lyophilization, the TFA salt of the desired product was obtained as a white solid.
JanusA-Nea (20) Synthesis of Janus-Guanidinoneamine ligands (24) (25) (26) (27) .
General procedure. Janus-Neamine ligand (20) (21) (22) (23) , 300 nmol) and 1,3-di-Boc-2-trifluoromethylsulfonyl)guanidine (4.7 mg, 12 µmol) were dissolved in a 5:3 (v/v) mixture of MeOH/CHCl 3 (0.5 mL) under argon atmosphere. Then, triethylamine (10 µL, 72 µmol) was added and the reaction mixture was stirred for 4 days at rt under Ar. After evaporation in vacuo, the crude was diluted with DCM (5 mL) and washed with a 10 % aqueous solution of citric acid (3×1 mL) and with brine (3×1 mL). The organic phase was taken up and dried over anhydrous MgSO 4 , filtered and concentrated in vacuo to dryness. The crude was dissolved in a 1:1 (v/v) mixture of TFA/DCM (0.5 mL) and TIS (12.5 µL, 61 µmol) was added. After stirring at rt for 2 h under Ar, the mixture was diluted with toluene (2 mL) and evaporated in vacuo. After several co-evaporations from toluene, the residue was dissolved in Milli-Q H 2 O (5 mL) and lyophilized to provide a white solid. Purification was carried out by analytical reversed-phase HPLC (linear gradient from 0 to 25% B in 35 min;
A: 0.045% TFA in H 2 O and B: 0.036% TFA in ACN), and the TFA salt of the desired product was obtained after lyophilization.
JanusA-NeaG4 (24) Evaluation of the interaction between Tau RNA and Janus-containing ligands.
Oligoribonucleotides were synthesized using 2'-O-tert-butyldimethylsilyl (TBDMS) protection and following standard procedures (phosphite triester approach). RNA, fluorescein and 2-AP phosphoramidites, solid-supports, reagents and solvents for oligoribonucleotide synthesis were purchased from Glen Research or Link Technologies.
The syntheses (1-µmol scale) were performed on an ABI 3400 DNA automatic synthesizer according to the manufacturer's synthesis procedure, with some modifications. 11a Cleavage 29 and deprotection from the solid support were carried out following a stepwise protocol. 11a,28 RNase-free reagents, solutions and materials were used when manipulating deprotected oligoribonucleotides. RNase-free water was obtained directly from a Milli-Q system equipped with a 5000 Da ultrafiltration cartridge. Reversed-phase high-performance liquid chromatography (HPLC) was used both for the analysis and purification of oligoribonucleotides using linear gradients of 0.1 M aqueous NH 4 HCO 3 , and a 1:1 mixture of 0.1 M aqueous NH 4 HCO 3 and ACN. Characterization was carried out by high resolution MALDI-TOF mass spectrometry (negative mode, 2,4,6-trihidroxyacetophenone matrix with ammonium citrate as an additive).
The following oligoribonucleotide sequences were synthesized (* label denotes that the ends of the chains were modified with 2'-O-methylribonucleosides): wt RNA:
5'rG*C*GGCAGUGUGAGUACCUUCACACGUCC*C*; +3 mutated RNA:
5'rG*C*GGCAGUGUAAGUACCUUCACACGUCC*C*; +16 mutated RNA:
5'rG*C*GGCAGUGUGAGUACCUUCACAUGUCC*C*. In fluorescence binding assays, NMR spectroscopy of RNA-ligand complexes. NMR spectra were acquired in a Bruker
Advance spectrometer operating at 600 MHz and equipped with a cryoprobe. Samples of the complexes were prepared by mixing the appropriate amounts of RNA and ligand and performing an annealing protocol consisting of heating to 90 °C for 3 min, followed by snap cooling on ice for 20 min. Samples were dissolved in 10 mM sodium phosphate, pH 6.8, in a 9:1 H 2 O-D 2 O mixture and NMR spectra were recorded at 5 °C to reduce the exchange with water. Water suppression was achieved by using an excitation sculpting sequence (zgesgp).
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